Schering Generic Ribavirin Carries PEG-Intron Indication; Valeant Will Receive Royalties
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering generic launches April 8, two days after FDA clears Three Rivers’ and Sandoz’ ribavirin ANDAs. All generics are expected to be priced at a 10% discount to Schering’s Rebetol.